Splitfin S.A. is a Brazilian multinational corporation with operations in Sao Palo, Palomar City, Frankfurt, Istanbul and Tehran. They license bio-medical designs and 3D bioware fabrication plots to third parties. Splitfin has a 48% market share in bio-interface rights-protection. The medical rights protection and rights-managed neuro-interface market is a US$38bn annual business.
The majority of the Splitfin consumer market is wetware white-labeled for rebranding by insurance companies and hospitals. Many of their products are printed or fabricated on-site at clinics and hospitals using Romy-Tech bio-med materials.
One of Splifin’s major clients is Romy Industries. Pike Street has had a love-hate outlook on this corporate relationship. Many question the decision to have such a major reliance on Romy Industries materials and distribution channels. A reported 40% of their revenue is derived from Romy licenses.
Splitfin S.A. is slated to complete construction on it’s Palomar City headquarters in fall 2044, the tower rises 78 stories above District 04.